Background: In a large proportion of patients with a mild to moderate bleeding ten-
| INTRODUC TI ON
Mild to moderate bleeding tendency is a frequent cause for detailed investigations of the plasmatic coagulation system and platelet function. However, in the majority of these patients no underlying bleeding disorder can be identified, leading to the categorization as patients with bleeding of unknown cause (BUC). [1] [2] [3] Although the bleeding phenotype and severity are not different from patients with a diagnosis of a specific bleeding disorder, 1 the mechanisms underlying the bleeding tendency are unknown in these patients.
Available routine coagulation tests, such as activated partial thromboplastin time (aPTT) and prothrombin time (PT), do not distinguish patients with BUC from healthy controls, 1,2 perhaps because the endpoint of measurement is the formation of a fibrin clot, which occurs when only 5% of thrombin is formed. 4 Therefore, a global test that evaluates both formation and decay of thrombin may better reflect the hemostatic potential of BUC patients. 5 Decreased generation of thrombin has been shown in patients with known coagulation disorders such as von Willebrand disease (VWD) and hemophilia. [6] [7] [8] [9] Although a previous small study by our group did not reveal disturbed thrombin generation in BUC patients compared to healthy controls, 10 data from a large cohort of patients with BUC are not available.
Analysis of clot formation, structure, and resistance to fibrinolysis is another method used to investigate hemostatic capacity. Altered clot characteristics have been reported in both thrombotic [11] [12] [13] [14] and bleeding disorders. 9, [15] [16] [17] In patients with hemophilia A and B, clot formation is delayed and results in looser clots with thicker fibrin fibers. 9, [15] [16] [17] In a small BUC patient cohort, our group demonstrated that in the presence of tissue plasminogen activator, the plasma clot formation rate is reduced in BUC patients compared to healthy controls. 18 The present study investigated the thrombin generation potential and clot formation and lysis in a large, well-defined cohort of patients with BUC from the VIBB. We aimed to determine whether these global assays reflect the hypocoagulable state of these patients.
| PATIENTS AND ME THODS

| Selection of patients with BUC and patients with factor VIII levels below 50%
Between October 2009 and November 2017, 547 adult patients with a mild to moderate bleeding tendency were recruited in the VIBB. 1 This ongoing single-center study included all patients /L) were also not included. All participants gave written informed consent before study inclusion. Routinely, a blood count, differential blood count, renal and liver function, and parameters of inflammation and iron deficiency were assessed in each patient. The detailed coagulation tests performed in every patient are listed in Table S1 . Each patient's personal medical and bleeding history was recorded by trained personnel at study inclusion. Bleeding severity was assessed using a standardized bleeding score (Vicenza bleeding score). 19 From
June 2013, we also recorded the ISTH-BAT bleeding score, which is available for 186 patients (34%). The Vicenza bleeding score, which correlated strongly with the ISTH-BAT bleeding score (R = 0.819, P value <0.001), was used for further analysis. 20 All procedures were or low VWF (VWF:Ag or VWF:RCo levels 30-50 IU/dL, n = 31) with FVIII > 50%, patients with FIX ≤ 50% (n = 5), FXI ≤ 60% (n = 3), FXIII ≤ 10% (n = 1), and three patients with hypofibrinogenemia/ dysfibrinogenemia were not included. None of our patients had alpha2-antiplasmin deficiency (<70%). 21, 22 In 382 patients no underlying cause for the bleeding tendency was identified, as all coagulation and platelet function tests revealed normal results.
These patients were categorized as BUC patients and are included in the current study.
In addition, we included 16 patients with factor VIII (FVIII) activity levels ≤ 50% from the VIBB for comparison. Of these, 8 patients had mild (FVIII activity: 21%-38%) and 1 patient had moderate
Essentials
• Many patients with a bleeding tendency lack a diagnosis (BUC).
• We compared thrombin generation, clot formation, and lysis of BUC patients and healthy controls.
• Thrombin generation and clot formation and lysis were significantly impaired in BUC patients.
• Bleeding severity did not correlate with thrombin generation or plasma clot properties. 
| Blood sampling
| Plasma clot formation and lysis assay
Plasma clot formation and lysis were turbidimetrically assessed using the method published by Wolberg et al 16, 24 The assays for clot formation and clot lysis were combined, as recommended by the SSC of the ISTH. 25 Briefly, calcium chloride (20 mM, final), 
| Statistical analysis
Statistical analyses were performed using the Statistical Package were used for adjustment comparing BUC patients and healthy controls. In case of comparison of BUC patients to FVIII patients, sex was used for adjustment. A P value of <0.05 was considered statistically significant.
| RE SULTS
| Clinical and laboratory characteristics of patients with BUC, healthy controls, and patients with FVIII deficiency
Clinical and laboratory characteristics of BUC patients in comparison to healthy controls and patients with FVIII ≤50% are shown in Table 1 . The majority of BUC patients were female (87%). Blood group O was the predominant blood type in both BUC patients and healthy controls. The BUC patients had a slightly but significantly higher body mass index compared to healthy controls. In the laboratory results, the prothrombin time, given in percentage of normal, was significantly lower; fibrinogen was significantly higher and factor XIII activity levels were lower in BUC patients than in healthy controls, whereas there was no significant difference compared to patients with FVIII ≤50%.
As expected, in patients with FVIII ≤50%, aPTT was significantly longer and levels of VWF:Ag, VWF:RCo, and FVIII activity were significantly lower than in BUC patients and healthy controls. Interestingly, there was no difference in the bleeding score between patients with BUC and those with FVIII ≤50%.
| Thrombin generation in patients with BUC compared to healthy controls and patients with FVIII deficiency
Thrombin generation was significantly impaired in patients with BUC compared to healthy controls (Table 2, Figure S1 ) and, as expected, in FVIII-deficient patients compared to healthy controls (Table S2 ). In the BUC patient group, the lag time was prolonged,
Representative curves of plasma clot formation and lysis from one patient with BUC, one patient with FVIII ≤50%, and one healthy control. ΔAbs, maximum absorbance at plateau; BUC, bleeding of unknown cause; CLT, clot lysis time; FVIII, factor VIII activity; TTP, time to peak showed significant differences in thrombin-generation parameters, with a shorter lag time, higher velocity index, higher peak thrombin, and shorter TTP. The AUC was equally impaired in patients with BUC and FVIII ≤ 50%.
| Clot formation and lysis in patients with BUC compared to healthy controls and patients with FVIII deficiency
Patients with BUC showed significantly altered clot formation, including a lower clot formation rate (Vmax), increased ΔAbs, prolonged TTP, and shorter CLT compared to healthy controls (Table 3 , TA B L E 1 Demographic and laboratory data of patients with BUC (n = 382) compared to healthy controls (n = 100) and patients with FVIII ≤ 50% (n = 16) Figure S2 ). There was no difference in the lag time between patients with BUC and healthy controls. In patients with FVIII deficiency, clot formation and lysis were significantly impaired in comparison to healthy controls (Table S3 ). Clot formation was even more impaired than in BUC patients, as indicated by a longer lag time, lower clot formation rate (Vmax), lower ΔAbs, and longer TTP. There was no TA B L E 3 Clot formation and lysis parameters in patients with BUC (n = 382) compared to healthy controls (n = 100) and patients with FVIII ≤ 50% (n = 16) difference in CLT between patients with FVIII ≤ 50% and BUC patients (Table 3) .
| Correlation of thrombin-generation parameters with clinical and laboratory parameters of patients with BUC and healthy controls
To identify a possible influence of clinical and laboratory characteristics on thrombin generation and clot formation and lysis, we calculated correlations in patients with BUC and healthy controls (Table 4 and Table 5 ). Thrombin generation parameters showed only weak correlations with clinical and laboratory characteristics. Both BUC patients and controls showed a weak, but consistent correlation between the aPTT and all thrombin-generation parameters, whereas the prothrombin time correlated with these parameters only in the control group. In both BUC patients and controls, FVIII and FIX activity correlated weakly with peak thrombin and velocity index, but not with the lag time. Fibrinogen and VWF:Ag correlated weakly with peak thrombin, velocity index, and AUC in the BUC patients, but not controls.
| Correlation of clot parameters with clinical and laboratory parameters of patients with BUC and healthy controls
We found weak to strong correlations between clinical and laboratory parameters and parameters of clot formation and lysis (Table 5) .
Fibrinogen showed the strongest correlation with plasma clot parameters, especially with Vmax and ΔAbs. Factor VIII, FIX, and FXIII activity also correlated weakly to moderately with clot turbidity (ΔAbs), clot formation rate (Vmax), and CLT in patients with BUC and controls. Neither aPTT nor PT showed any consistent correlations with plasma clot parameters in either BUC patients or controls.
There was also no correlation between bleeding score and clot formation or lysis parameters.
| Cut off values of thrombin generation, clot formation, and clot lysis parameters
We also analyzed thrombin generation, clot formation, and clot lysis parameters using cutoffs defined by the 25th/75th and TA B L E 5 Correlation of plasma clot parameters with clinical and laboratory parameters in patients with BUC (n = 382) and healthy controls (n = 100) 5th/95th percentiles of healthy controls (Table S4) . For all analyzed parameters, values above or below the 25th and 75th percentiles occurred more often in patients with BUC than in healthy controls. Values above or below the 5th and 95th percentiles occurred more often in patients with BUC than in healthy controls in velocity index, peak thrombin, and AUC of thrombin generation and all parameters of plasma clot properties except ΔAbs.
| Thrombin generation and clot formation and lysis in BUC patients according to their bleeding severity
There were no correlations between parameters of thrombin generation or plasma clot formation and bleeding score (Table 4 and Table5). In a separate analysis we investigated a potential difference between patients with a "nonpathological" bleeding severity (BS below the cutoff) and patients with a bleeding score above the gender-specific cutoff (≥3 for males und ≥5 for females) 20 as well as healthy controls (Table 6 ). A total of 139 patients (36.4%) had a BS below and 243 patients (63.6 %) above the gender-specific cutoff.
Comparison of BUC patients with an abnormal BS to BUC patients with a BS below the cutoff did not show significant differences in any of the analyzed parameters (Table 6 ). Moreover, all parameters of thrombin generation were still impaired in BUC patients with a bleeding score below the predefined threshold in comparison to healthy controls. Also compared to healthy controls, patients with a BS below the cutoff had a reduced clot formation rate, increased
ΔAbs, and shortened clot lysis time (Table 6 ).
| D ISCUSS I ON
In this study we observed that thrombin generation and clot forma- TA B L E 6 Thrombin-generation parameters and clot formation and lysis parameters in BUC patients with a bleeding score below the gender-specific cutoff (≥3 for males and ≥5 for females; n = 139) compared to BUC patients with a bleeding score above the cutoff (n = 243) and healthy controls with BUC. This observation is in line with a recent meta-analysis indicating that bleeding assessment tools lack sufficient sensitivity and specificity to discriminate patients with and without mild bleeding disorders. 26 Whereas most parameters of thrombin generation and plasma clot properties correlated strongly in controls, correlations were mostly weak in BUC patients (Table   S5) . Therefore, the alterations in plasma clot formation in our group of BUC patients are only insufficiently explained by the decreased generation of thrombin.
The mechanisms underlying the delayed and decreased thrombin generation and plasma clot formation in our patients with BUC remain unclear. Most of the alterations that we found in BUC patients were similar, though less pronounced than those seen in FVIII-deficient patients, suggesting some of the hemostatic defect may be common to both of these groups of patients. One possible mechanism might be increased inhibitor antigen or activity, 27 which would not be detected by global coagulation tests. For example, Dargaud et al described a thrombomodulin mutation leading to elevated levels of soluble thrombomodulin, enhanced protein C activation, and impaired thrombin generation (decreased AUC) in a patient with a bleeding tendency and otherwise normal coagulation screening tests. 28 A gain-of-function mutation in Factor V that leads to increased circulating TFPI, decreased thrombin formation, and bleeding was also recently described. [29] [30] [31] In those patients, routine global tests of aPTT and prothrombin time were also affected.
Altered expression of fibrinogen isoforms that have anticoagulant activity (γ') 32,33 might also modify thrombin generation and clot formation and lysis in a manner that is not detected by conventional coagulation assays. Future studies, including analysis of soluble thrombomodulin, free TFPI, and fibrinogen γ' levels, are warranted to identify the underlying mechanisms contributing to bleeding in these patients.
In a previous study of Ay et.al., we were not able to detect a difference in thrombin generation in BUC patients compared to healthy controls, which is in contrast to the current study. 10 This discrepancy might be explained by variation in patient selection and by the much smaller sample size in the previous cohort. In line with the significantly deteriorated clot formation in this study, we have also shown a slower clot formation rate (Vmax) in the presence of rtPA in a previous study on a smaller group of patients with BUC. 18 Ryan et al reported that at constant fibrinogen concentrations, low concentrations of thrombin lead to a slower formation of clots containing thicker fibrin fibers. Thus, the reduced thrombin generation might underlie the slower formation and increased turbidity of the clots in our BUC patient group. We found a shorter CLT, indicating increased susceptibility of the clots of BUC patients to lysis, which has previously also been observed in a group of women with heavy menstrual bleeding without known hemostatic abnormalities. 34 Moreover, in a previous investigation of fibrinolysis parameters in plasmas from patients with BUC we showed that increased fibrinolysis might underlie the bleeding tendency in at least some of the patients. 35 The findings of increased clot fibrinolytic susceptibility in patients with BUC are also supported by the clinical efficacy of antifibrinolytic agents such as tranexamic acid for treating mild to moderate bleeding symptoms. [36] [37] [38] Our study has several limitations. First, the bleeding phenotype of the investigated patients was mild and according to the bleeding score cutoffs (abnormal bleeding score: adult men ≥3, adult women ≥5), 36.4% of our patients with BUC would not be considered to have a bleeding disorder. 20 However, there was no difference in thrombin generation or clot formation and lysis between patients below and above this cutoff, whereas patients with a defined nonpathological bleeding score still had significantly impaired results compared to healthy controls (Table 6 ). This is further underlined as there was no difference in the bleeding severity between our group of patients with BUC and patients with FVIII activity ≤50%. Second, we were able to include only a small group of patients with FVIII ≤50% for comparison. This is due to the strict and specific inclusion criteria of the VIBB, which recruits only patients with a bleeding tendency without a previous diagnosis of an established bleeding disorder. Third, the tests performed are nonphysiological ex vivo tests and therefore do not completely reflect the clotting cascade in vivo. However, prior studies have associated parameters from these assays with clinically relevant outcomes. 9,11-15 Finally, we measured dynamic changes in plasma clot formation and lysis, but we did not explicitly investigate clot structure by scanning electron microscopy or clot permeability because of limited sample volume. Thus, refined plasma clot properties in the setting of mild bleeding disorders have yet to be thoroughly characterized.
In conclusion, our data show a reduced hemostatic potential and increased susceptibility to clot lysis in patients with BUC.
Thrombin-generation parameters, the clot formation rate, and clot lysis time distinguished patients with a mild to moderate bleeding tendency without diagnosis of an established bleeding disorder from healthy controls. The comparison to patients with a known impairment of thrombin generation and plasma clot formation (patients with FVIII ≤50%) validates our assessments and supports the conclusion of a dysfunctional process of coagulation in our patients with BUC. These assays might alert physicians to the hemostatic impairment in patients with otherwise normal coagulation test results and raise awareness of an increased bleeding risk, especially in situations of hemostatic challenges. Our data warrant further investigations on the mechanisms underlying the reduced hemostatic potential and accelerated clot lysis in our patients with BUC.
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